Skip to main content
SpringerLink
Log in

Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis

  • Chapter
  • First Online:
Medical Therapy of Ulcerative Colitis

  • 1232 Accesses

Abstract

Ulcerative colitis (UC) is associated with a spectrum of hepatobiliary diseases which can be classified into 3 groups: (1) hepatobiliary diseases with association to UC or possibly shared pathogenesis with UC, (2) hepatobiliary disease with association to UC therapy, and (3) hepatobiliary diseases encountered in UC, which may relate to physiological changes from UC. Among these abnormalities, the most common condition is primary sclerosing cholangitis (PSC). A diagnosis of PSC is based on a constellation of clinical, biochemical, and typical cholangiographic features. The response to a variety of medical therapies for PSC has varied. UDCA has been widely utilized for PSC, but recent data noted that high-dose UDCA may be harmful. Other common associated hepatobiliary conditions include fatty liver, gallstones, and drug-induced liver injury, as well as potential reactivation of chronic hepatitis B from immunosuppressive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut. 1994;35(1):84–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Yamamoto-Furusho JK, Sanchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010;9(4):397–401.

    PubMed  Google Scholar 

  3. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13(9):1106–14.

    PubMed  Google Scholar 

  4. Riegler G, D’Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol. 1998;33(1):93–8.

    CAS  PubMed  Google Scholar 

  5. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(9):1598–619.

    PubMed  Google Scholar 

  6. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–22.

    CAS  PubMed  Google Scholar 

  7. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis–aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48 Suppl 1:S38–57.

    PubMed  Google Scholar 

  8. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78.

    CAS  PubMed  Google Scholar 

  9. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol Mar. 2002;36(3):321–7.

    Google Scholar 

  10. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364–9.

    PubMed  Google Scholar 

  11. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48(6):939–44.

    PubMed  Google Scholar 

  12. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102(5):1042–9.

    PubMed  Google Scholar 

  13. Shorbagi A, Bayraktar Y. Primary sclerosing cholangitis – what is the difference between east and west? World J Gastroenterol. 2008;14(25):3974–81.

    PubMed Central  PubMed  Google Scholar 

  14. Thia KT, Loftus Jr EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103(12):3167–82.

    PubMed  Google Scholar 

  15. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38(4):610–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10(4):430–6.

    CAS  PubMed  Google Scholar 

  17. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastroenterol. 1997;32(6):604–10.

    CAS  PubMed  Google Scholar 

  18. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100(5 Pt 1):1319–23.

    CAS  PubMed  Google Scholar 

  19. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan – analysis of 192 cases. J Gastroenterol. 1997;32(1):134–7.

    CAS  PubMed  Google Scholar 

  20. Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008;28(7):983–9.

    CAS  PubMed  Google Scholar 

  21. Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21(5):787–91.

    CAS  PubMed  Google Scholar 

  22. Kochhar R, Goenka MK, Das K, et al. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol. 1996;11(5):429–33.

    CAS  PubMed  Google Scholar 

  23. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126(7):1929–30.

    PubMed  Google Scholar 

  24. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26(1):31–41.

    PubMed  Google Scholar 

  25. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev. 2005;4(3):137–43.

    CAS  PubMed  Google Scholar 

  26. Chandra NCS, Chapman RW. Primary sclerosing cholangitis. In: McDonald JWDBA, Feagan BG, Fennerty MB, editors. Evidence-based gastroenterology and hepatology. 3rd ed. Chichester, UK: Blackwell; 2010. p. 533–53.

    Google Scholar 

  27. Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol. 2007;13(41):5421–31.

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15(4):629–42.

    CAS  PubMed  Google Scholar 

  29. Terjung B, Sohne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut. 2010;59(6):808–16.

    CAS  PubMed  Google Scholar 

  30. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(11):3195–9.

    CAS  PubMed  Google Scholar 

  31. Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol. 2005;42(2):252–6.

    PubMed  Google Scholar 

  32. Karlsen TH, Hampe J, Wiencke K, et al. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol. 2007;102(1):115–21.

    CAS  PubMed  Google Scholar 

  33. Karlsen TH, Boberg KM, Vatn M, et al. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun. 2007;8(3):275–8.

    CAS  PubMed  Google Scholar 

  34. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138(3):1102–11.

    PubMed  Google Scholar 

  35. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43(1):17–9.

    CAS  PubMed  Google Scholar 

  36. Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology. 2011;53(6):1977–85.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Hov JR, Keitel V, Laerdahl JK, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One. 2010;5(8):e12403.

    PubMed Central  PubMed  Google Scholar 

  38. Mandal A, Dasgupta A, Jeffers L, et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology. 1994;106(1):185–92.

    CAS  PubMed  Google Scholar 

  39. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology. 2007;132(4):1504–14.

    CAS  PubMed  Google Scholar 

  40. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut. 2002;51(1):120–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Spirli C, Fabris L, Duner E, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology. 2003;124(3):737–53.

    CAS  PubMed  Google Scholar 

  42. Karlsen TH, Lie BA, Frey Froslie K, et al. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology. 2006;131(3):781–7.

    CAS  PubMed  Google Scholar 

  43. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127(1):261–74.

    CAS  PubMed  Google Scholar 

  44. Pauli-Magnus C, Kerb R, Fattinger K, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 2004;39(3):779–91.

    CAS  PubMed  Google Scholar 

  45. van den Ent F, Amos L, Lowe J. Bacterial ancestry of actin and tubulin. Curr Opin Microbiol. 2001;4(6):634–8.

    PubMed  Google Scholar 

  46. Palmer KR, Duerden BI, Holdsworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut. 1980;21(10):851–4.

    CAS  PubMed Central  PubMed  Google Scholar 

  47. Bjornsson E, Cederborg A, Akvist A, Simren M, Stotzer PO, Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2005;40(9):1090–4.

    PubMed  Google Scholar 

  48. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102(1):107–14.

    PubMed  Google Scholar 

  49. Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2004;39(10):961–8.

    CAS  PubMed  Google Scholar 

  50. Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol. 2009;104(4):855–60.

    PubMed  Google Scholar 

  51. Ponsioen CY, Reitsma JB, Boberg KM, Aabakken L, Rauws EA, Schrumpf E. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy. 2010;42(9):742–7.

    CAS  PubMed  Google Scholar 

  52. Braden B, Faust D, Ignee A, Schreiber D, Hirche T, Dietrich CF. Clinical relevance of perihepatic lymphadenopathy in acute and chronic liver disease. J Clin Gastroenterol. 2008;42(8):931–6.

    PubMed  Google Scholar 

  53. Johnson KJ, Olliff JF, Olliff SP. The presence and significance of lymphadenopathy detected by CT in primary sclerosing cholangitis. Br J Radiol. 1998;71(852):1279–82.

    CAS  PubMed  Google Scholar 

  54. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52(11):3123–35.

    CAS  PubMed  Google Scholar 

  55. Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology. 2002;35(3):652–7.

    PubMed  Google Scholar 

  56. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688–94.

    CAS  PubMed  Google Scholar 

  57. Talwalkar JA, Seaberg E, Kim WR, Wiesner RH. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score. National Institutes of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Group. Liver Transpl. 2000;6(6):753–8.

    CAS  PubMed  Google Scholar 

  58. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33(6):854–62.

    PubMed  Google Scholar 

  59. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004;8(1):67–81. vi.

    PubMed  Google Scholar 

  60. European Association for the Study of the Liver. Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.

    Google Scholar 

  61. Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms – IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33(12):1273–91.

    CAS  PubMed  Google Scholar 

  62. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336(10):691–5.

    CAS  PubMed  Google Scholar 

  63. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121(4):900–7.

    CAS  PubMed  Google Scholar 

  64. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(5):1558–62.

    CAS  PubMed  Google Scholar 

  65. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008;48(5):792–800.

    CAS  PubMed  Google Scholar 

  66. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464–72.

    CAS  PubMed  Google Scholar 

  67. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–14.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(9):2333–7.

    CAS  PubMed  Google Scholar 

  69. Giljaca V, Poropat G, Stimac D, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2010;1, CD004036.

    PubMed  Google Scholar 

  70. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol. 1991;86(1):57–61.

    CAS  PubMed  Google Scholar 

  71. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med. 1999;131(12):943–6.

    CAS  PubMed  Google Scholar 

  72. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994;106(2):494–9.

    CAS  PubMed  Google Scholar 

  73. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol. 1996;91(3):511–5.

    CAS  PubMed  Google Scholar 

  74. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2005;100(2):308–12.

    CAS  PubMed  Google Scholar 

  75. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 2007;27(4):451–3.

    CAS  PubMed  Google Scholar 

  76. Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 1993;34(2):242–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(5):522–6.

    CAS  PubMed  Google Scholar 

  78. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology. 1988;95(4):1036–42.

    CAS  PubMed  Google Scholar 

  79. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology. 1995;108(4):1199–203.

    CAS  PubMed  Google Scholar 

  80. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci. 2008;53(6):1716–20.

    CAS  PubMed  Google Scholar 

  81. Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2009;104(1):83–8.

    CAS  PubMed  Google Scholar 

  82. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31(1):7–11.

    CAS  PubMed  Google Scholar 

  83. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50(9):1734–40.

    CAS  PubMed  Google Scholar 

  84. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48(4):1106–17.

    CAS  PubMed  Google Scholar 

  85. Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ. Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am. 2009;18(2):325–37. ix.

    PubMed  Google Scholar 

  86. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54.

    PubMed  Google Scholar 

  87. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94(6):1643–9.

    CAS  PubMed  Google Scholar 

  88. Brandt DJ, MacCarty RL, Charboneau JW, LaRusso NF, Wiesner RH, Ludwig J. Gallbladder disease in patients with primary sclerosing cholangitis. Am J Roentgenol. 1988;150(3):571–4.

    CAS  Google Scholar 

  89. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol. 2007;31(6):907–13.

    PubMed  Google Scholar 

  90. Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97(5):1138–42.

    PubMed  Google Scholar 

  91. Leung UC, Wong PY, Roberts RH, Koea JB. Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply? ANZ J Surg. 2007;77(5):355–7.

    PubMed  Google Scholar 

  92. Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(9):727–38.

    PubMed  Google Scholar 

  93. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330–40.

    PubMed  Google Scholar 

  94. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6(6):1422–9.

    CAS  PubMed  Google Scholar 

  95. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002;35(2):380–4.

    PubMed Central  PubMed  Google Scholar 

  96. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(8):797–813.

    PubMed  Google Scholar 

  97. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology. 2001;33(1):301–7.

    CAS  PubMed  Google Scholar 

  98. Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140(1):180–8.

    PubMed Central  PubMed  Google Scholar 

  99. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134(4):975–80.

    PubMed  Google Scholar 

  100. Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008;47(1):133–42.

    CAS  PubMed  Google Scholar 

  101. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374–85.

    PubMed  Google Scholar 

  102. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38.

    CAS  PubMed  Google Scholar 

  103. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008;28(2):209–20.

    CAS  PubMed  Google Scholar 

  104. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100(7):1516–22.

    PubMed  Google Scholar 

  105. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706–15.

    PubMed  Google Scholar 

  106. Narula N, Vasudev M, Marshall JK. IgG-related sclerosing disease: a novel mimic of inflammatory bowel disease. Dig Dis Sci. 2010;55(11):3047–51.

    CAS  PubMed  Google Scholar 

  107. Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34(1):88–94.

    PubMed  Google Scholar 

  108. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070–5.

    CAS  PubMed  Google Scholar 

  109. McGowan CE, Jones P, Long MD, Barritt AS. Changing shape of disease: nonalcoholic fatty liver disease in Crohn’s disease – a case series and review of the literature. Inflamm Bowel Dis. 2011;18(1):49–54.

    PubMed Central  PubMed  Google Scholar 

  110. Baker ME, Remzi F, Einstein D, et al. CT depiction of portal vein thrombi after creation of ileal pouch-anal anastomosis. Radiology. 2003;227(1):73–9.

    PubMed  Google Scholar 

  111. Ball CG, MacLean AR, Buie WD, Smith DF, Raber EL. Portal vein thrombi after ileal pouch-anal anastomosis: its incidence and association with pouchitis. Surg Today. 2007;37(7):552–7.

    PubMed  Google Scholar 

  112. Remzi FH, Fazio VW, Oncel M, et al. Portal vein thrombi after restorative proctocolectomy. Surgery. 2002;132(4):655–61. discussion 661–2.

    PubMed  Google Scholar 

  113. Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol. 2003;9(4):878–80.

    PubMed  Google Scholar 

  114. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7(4):295–300.

    CAS  PubMed  Google Scholar 

  115. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28(3):508–18.

    PubMed  Google Scholar 

  116. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  117. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103(6):1925–7.

    CAS  PubMed  Google Scholar 

  119. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102(7):1518–27.

    CAS  PubMed  Google Scholar 

  120. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23. quiz 524.

    PubMed  Google Scholar 

  121. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(6):619–33.

    CAS  PubMed  Google Scholar 

  122. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007;102(11):2488–94.

    CAS  PubMed  Google Scholar 

  123. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940–87.

    CAS  PubMed  Google Scholar 

  124. Ansari A, Elliott T, Baburajan B, et al. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):734–41.

    CAS  PubMed  Google Scholar 

  125. Seksik P, Mary JY, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis. 2011;17(2):565–72.

    PubMed  Google Scholar 

  126. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol. 2005;43(2):303–9.

    CAS  PubMed  Google Scholar 

  127. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3150–6.

    CAS  PubMed  Google Scholar 

  128. Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105(7):1620–6.

    CAS  PubMed  Google Scholar 

  129. Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37(3):316–28.

    CAS  PubMed  Google Scholar 

  130. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160(3):622–8.

    CAS  PubMed  Google Scholar 

  131. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.

    CAS  PubMed  Google Scholar 

  132. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200.

    PubMed  Google Scholar 

  133. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    PubMed  Google Scholar 

  134. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11(4):965–91. x.

    PubMed  Google Scholar 

  135. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(6):925–32.

    PubMed  Google Scholar 

  136. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49 Suppl 5:S156–65.

    CAS  PubMed  Google Scholar 

  137. Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59(10):1340–6.

    CAS  PubMed  Google Scholar 

  138. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132(9):331–5.

    Google Scholar 

  139. Chaparro M, Nogueiras AR, Menchen LA, Marin-Jimenez I, Garcia-Sanchez V, Villagrasa JR, Gisbert JP. Comparative study to evaluate the effectiveness of two different vaccination protocols against hepatitis B virus in inflammatory bowel disease patients. Gastroenterology. 2011;140(5 (Suppl 1)):S587–8.

    Google Scholar 

  140. Barraclough KA, Wiggins KJ, Hawley CM, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis. 2009;54(1):95–103.

    PubMed  Google Scholar 

  141. Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198(3):299–304.

    PubMed  Google Scholar 

  142. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine. 1997;15(4):353–6.

    CAS  PubMed  Google Scholar 

  143. Chaparro M, Nogueiras AR, Villagrasa JR, Gisbert JP. Kinetics of the anti-HBs titers after vaccination against hepatitis B virus in patients with inflammatory bowel disease. Gastroenterology. 2011;140(5 (Suppl 1)):S589.

    Google Scholar 

  144. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15(2):89–102.

    CAS  PubMed  Google Scholar 

  145. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009;9(8):1707–13.

    CAS  PubMed  Google Scholar 

  146. Seow CH, Benchimol EI, Griffiths AM, Steinhart AH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2008;3, CD006790.

    PubMed  Google Scholar 

  147. Bargiggia S, Thorburn D, Anderloni A, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005;22(3):209–15.

    CAS  PubMed  Google Scholar 

  148. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41 e31.

    CAS  PubMed  Google Scholar 

  149. Kotlyar DS, Blonski W, Diamond RH, Wasik M, Lichtenstein GR. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010;105(10):2299–301.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Phialdephia, PA, 19104, USA

    Chalermrat Bunchorntavakul M.D. & K. Rajender Reddy M.D.

  2. Division of Gastroenterology and Hepatology, Department of Medicine, Rajavithi Hospital, 2 Phaya-Thai road, Ratchathewi, Bangkok, 10400, Thailand

    Chalermrat Bunchorntavakul M.D.

Authors
  1. Chalermrat Bunchorntavakul M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Rajender Reddy M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Rajender Reddy M.D. .

Editor information

Editors and Affiliations

  1. Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Gary R. Lichtenstein

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bunchorntavakul, C., Reddy, K.R. (2014). Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis. In: Lichtenstein, G. (eds) Medical Therapy of Ulcerative Colitis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1677-1_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1677-1_41

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1676-4

  • Online ISBN: 978-1-4939-1677-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation